Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor- α and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma

L. M. Minasian, T. P. Szatrowski, M. Rosenblum, T. Steffens, M. E. Morrison, P. B. Chapman, Lawrence Williams, C. F. Nathan, A. N. Houghton

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Hemorrhagic tumor necrosis is an inflammatory event that leads to selective destruction of malignant tissues, with both potentially toxic and beneficial consequences. A pilot clinical trial was undertaken combining tumor necrosis factor-α (TNF-α) with the monoclonal antibody R24 (MoAb R24) against GD3 ganglioside in patients with metastatic melanoma. Patients received MoAb R24 to recruit leukocytes to the tumor followed by low doses of recombinant TNF-α to activate leukocytes. Eight patients were treated and seven patients had mild toxicity. One patient with extensive metastatic melanoma developed tumor lysis syndrome within hours after treatment with almost complete necrosis of bulky tumors in multiple visceral sites. To our knowledge, this is the first documented case of hemorrhagic tumor necrosis in a patient with metastatic cancer in multiple visceral sites.

Original languageEnglish (US)
Pages (from-to)56-64
Number of pages9
JournalBlood
Volume83
Issue number1
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Tumors
Melanoma
Necrosis
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Neoplasms
Leukocytes
Tumor Lysis Syndrome
Poisons
Toxicity
GD3 ganglioside
Tissue
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Minasian, L. M., Szatrowski, T. P., Rosenblum, M., Steffens, T., Morrison, M. E., Chapman, P. B., ... Houghton, A. N. (1994). Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor- α and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood, 83(1), 56-64.
Minasian, L. M. ; Szatrowski, T. P. ; Rosenblum, M. ; Steffens, T. ; Morrison, M. E. ; Chapman, P. B. ; Williams, Lawrence ; Nathan, C. F. ; Houghton, A. N. / Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor- α and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. In: Blood. 1994 ; Vol. 83, No. 1. pp. 56-64.
@article{1ce67eb269b542e1bd236749f6a4a1c2,
title = "Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor- α and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma",
abstract = "Hemorrhagic tumor necrosis is an inflammatory event that leads to selective destruction of malignant tissues, with both potentially toxic and beneficial consequences. A pilot clinical trial was undertaken combining tumor necrosis factor-α (TNF-α) with the monoclonal antibody R24 (MoAb R24) against GD3 ganglioside in patients with metastatic melanoma. Patients received MoAb R24 to recruit leukocytes to the tumor followed by low doses of recombinant TNF-α to activate leukocytes. Eight patients were treated and seven patients had mild toxicity. One patient with extensive metastatic melanoma developed tumor lysis syndrome within hours after treatment with almost complete necrosis of bulky tumors in multiple visceral sites. To our knowledge, this is the first documented case of hemorrhagic tumor necrosis in a patient with metastatic cancer in multiple visceral sites.",
author = "Minasian, {L. M.} and Szatrowski, {T. P.} and M. Rosenblum and T. Steffens and Morrison, {M. E.} and Chapman, {P. B.} and Lawrence Williams and Nathan, {C. F.} and Houghton, {A. N.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "83",
pages = "56--64",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

Minasian, LM, Szatrowski, TP, Rosenblum, M, Steffens, T, Morrison, ME, Chapman, PB, Williams, L, Nathan, CF & Houghton, AN 1994, 'Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor- α and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma', Blood, vol. 83, no. 1, pp. 56-64.

Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor- α and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. / Minasian, L. M.; Szatrowski, T. P.; Rosenblum, M.; Steffens, T.; Morrison, M. E.; Chapman, P. B.; Williams, Lawrence; Nathan, C. F.; Houghton, A. N.

In: Blood, Vol. 83, No. 1, 01.01.1994, p. 56-64.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor- α and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma

AU - Minasian, L. M.

AU - Szatrowski, T. P.

AU - Rosenblum, M.

AU - Steffens, T.

AU - Morrison, M. E.

AU - Chapman, P. B.

AU - Williams, Lawrence

AU - Nathan, C. F.

AU - Houghton, A. N.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Hemorrhagic tumor necrosis is an inflammatory event that leads to selective destruction of malignant tissues, with both potentially toxic and beneficial consequences. A pilot clinical trial was undertaken combining tumor necrosis factor-α (TNF-α) with the monoclonal antibody R24 (MoAb R24) against GD3 ganglioside in patients with metastatic melanoma. Patients received MoAb R24 to recruit leukocytes to the tumor followed by low doses of recombinant TNF-α to activate leukocytes. Eight patients were treated and seven patients had mild toxicity. One patient with extensive metastatic melanoma developed tumor lysis syndrome within hours after treatment with almost complete necrosis of bulky tumors in multiple visceral sites. To our knowledge, this is the first documented case of hemorrhagic tumor necrosis in a patient with metastatic cancer in multiple visceral sites.

AB - Hemorrhagic tumor necrosis is an inflammatory event that leads to selective destruction of malignant tissues, with both potentially toxic and beneficial consequences. A pilot clinical trial was undertaken combining tumor necrosis factor-α (TNF-α) with the monoclonal antibody R24 (MoAb R24) against GD3 ganglioside in patients with metastatic melanoma. Patients received MoAb R24 to recruit leukocytes to the tumor followed by low doses of recombinant TNF-α to activate leukocytes. Eight patients were treated and seven patients had mild toxicity. One patient with extensive metastatic melanoma developed tumor lysis syndrome within hours after treatment with almost complete necrosis of bulky tumors in multiple visceral sites. To our knowledge, this is the first documented case of hemorrhagic tumor necrosis in a patient with metastatic cancer in multiple visceral sites.

UR - http://www.scopus.com/inward/record.url?scp=0027976678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027976678&partnerID=8YFLogxK

M3 - Article

VL - 83

SP - 56

EP - 64

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -

Minasian LM, Szatrowski TP, Rosenblum M, Steffens T, Morrison ME, Chapman PB et al. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor- α and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood. 1994 Jan 1;83(1):56-64.